{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:07Z","timestamp":1790312407969,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>This retrospective cohort study aimed to characterize the real-world clinical outcomes and treatment-emergent adverse events (TEAEs) of anlotinib-containing regimens among pediatric patients with solid tumors treated at the Children\u2019s Hospital of Zhejiang University School of Medicine from January 2020 to May 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 45 eligible patients treated with anlotinib at the Children\u2019s Hospital of Zhejiang University School of Medicine from January 2020 to May 2025; eligibility required age &amp;lt;18 years at solid tumor diagnosis, first-time anlotinib use at our center, RECIST 1.1-measurable disease, and available clinical and imaging data. Progression-free survival (PFS) was the primary endpoint, and objective response rate (ORR), disease control rate (DCR), and overall survival (OS) were secondary endpoints. Safety was assessed using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The observed ORR was 8.9% (4\/45), and the DCR was 40.0% (18\/45; 4 partial responses and 14 cases of stable disease). The median PFS was 5.6 months (95% CI: 2.9\u20138.3), while the median OS was not reached after seven deaths. Patients with other solid tumors (n=21) had an ORR of 19.0%, a DCR of 57.1%, and a median PFS of 9.4 months, compared with 0%, 25.0%, and 3.0 months, respectively, among patients with sarcomas (n=24). The observed DCR was 80.0% among patients without metastatic or recurrent disease (n=10) and 28.6% among those with metastatic or recurrent disease (n=35). DCRs were 33.3%, 48.0%, and 0% in the usual-dose (n=18), low-dose (n=25), and high-dose (n=2) groups, respectively; exploratory analyses did not detect statistically significant differences in DCR (p=0.393) or PFS distributions (p=0.395) across the three groups. Exploratory analyses did not detect statistically significant differences across the treatment-regimen groups in ORR (p=0.133), DCR (p=0.454), or PFS distributions (p=0.480). TEAEs were documented in 97.8% of patients, with grade 3\u20134 TEAEs observed in 84.4%. Hematologic TEAEs were the most frequently documented category (91.1%). Frequent non-hematologic events included pyrexia (62.2%), proteinuria (35.6%), hypokalemia (33.3%), and hypoalbuminemia (33.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this small, heterogeneous, single-center Chinese pediatric cohort, patients receiving anlotinib-containing regimens had limited objective response and a high incidence of grade 3\u20134 TEAEs, predominantly involving hematologic events. Subgroup findings were exploratory and may reflect selection bias, confounding by indication, tumor heterogeneity, and concomitant therapies. Larger prospective studies are required before comparative treatment or dosing conclusions can be made.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1722123","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:27:31Z","timestamp":1790310451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical outcomes and safety of anlotinib-containing regimens in pediatric solid tumors: a retrospective cohort study at a Chinese center"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiaoli","family":"Hua","sequence":"first","affiliation":[{"name":"Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University","place":["Hangzhou, Zhejiang, China"]},{"name":"National Clinical Trial Institute, Children\u2019s Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqi","family":"Xia","sequence":"additional","affiliation":[{"name":"Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University","place":["Hangzhou, Zhejiang, China"]},{"name":"National Clinical Trial Institute, Children\u2019s Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Gu","sequence":"additional","affiliation":[{"name":"Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University","place":["Hangzhou, Zhejiang, China"]},{"name":"National Clinical Trial Institute, Children\u2019s Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhu","family":"Wang","sequence":"additional","affiliation":[{"name":"Pediatric Cancer Research Center, National Clinical Research Center for Child Health","place":["Hangzhou, Zhejiang, China"]},{"name":"Department of Surgical Oncology, Children\u2019s Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health","place":["Hangzhou, Zhejiang, China"]},{"name":"Key Laboratory of Diagnosis and Treatment of Neonatal Diseases of Zhejiang Province","place":["Hangzhou, Zhejiang, China"]},{"name":"Cancer Center, Zhejiang University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqing","family":"Ni","sequence":"additional","affiliation":[{"name":"Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University","place":["Hangzhou, Zhejiang, China"]},{"name":"National Clinical Trial Institute, Children\u2019s Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","unstructured":"Childhood Cancer\n          \n          2026"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01541-0","article-title":"Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study","volume":"400","author":"Ni","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.711704","article-title":"The efficacy and safety of anlotinib in pediatric patients with refractory or recurrent solid tumors","volume":"13","author":"Lu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40880-019-0383-7","article-title":"China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy","volume":"39","author":"Zhou","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2950","article-title":"Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIb trial","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103258","article-title":"Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia\/Ib trial","volume":"84","author":"Lu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24562","article-title":"Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"60","author":"Warren","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B12","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0\n          \n          2017"},{"key":"B13","volume-title":"Medical Dictionary for Regulatory Activities (Meddra), Version 25.0","year":"2022"},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26448","article-title":"Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: results of a phase II study","volume":"64","author":"Modak","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04756-5","article-title":"Molecular genomic landscape of pediatric solid tumors in Chinese patients: implications for clinical significance","volume":"149","author":"Gong","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01856-6","article-title":"Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer","volume":"28","author":"Church","year":"2022","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","article-title":"Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma","volume":"28","author":"Su","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11776-4","article-title":"Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.719836","article-title":"Vascular normalization: a new window opened for cancer therapies","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00134-7","article-title":"Dose selection of novel anticancer drugs: exposing the gap between selected and required doses","volume":"25","author":"Op 't Hoog","year":"2024","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100943","article-title":"An overview of the BOIN design and its current extensions for novel early-phase oncology trials","volume":"28","author":"Ananthakrishnan","year":"2022","journal-title":"Contemp Clin Trials Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1722123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:27:33Z","timestamp":1790310453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1722123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1722123"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1722123","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1722123"}}